Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Venus Medtech (Hangzhou), Inc. Class H (2500) Stock Price & Analysis

1 Followers

2500 Stock Chart & Stats

HK$1.01HK$0.02(2.03%)
At close: 4:00 PM GMT+8
HK$1HK$1.1HK$1.2HK$1.3Aug 10Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2
Day’s Range
HKD 1.00 - HKD 1.11
52-Week Range
HKD 0.94 - HKD 3.86
Previous Close
HKD 0.99
Volume
N/A
Average Volume (3M)
323.30K
Market Cap
HKD 434.40M
Enterprise Value
HKD 670.90M
Total Cash (Recent Filing)
HKD 88.20M
Total Debt (Recent Filing)
HKD 202.65M
Price to Earnings (P/E)
―
Beta
0.57
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialized Structural-heart Focus

A focused structural-heart portfolio gives the company a defined position in minimally invasive treatment of valvular disease. Continued commercialization of transcatheter valves and related products can support durable participation in a specialized medical-device market over the next several quarters.

Improving Balance-sheet Leverage

The reduction in debt-to-equity indicates lower balance-sheet leverage and comparatively reduced financial risk. This provides greater flexibility to sustain operations and invest in commercialization while the company works through ongoing profitability and cash-generation challenges.

Still-solid Gross Margins

Maintained gross margins suggest the products continue to generate meaningful contribution before operating expenses. If revenue stabilizes, this margin foundation could help the company convert sales into improved operating performance, although substantial cost control is still required to reach profitability.

Bears Say

Sharp Revenue Deterioration

The sharp 2025 revenue decline weakens near-term operating scale and makes fixed commercial and development costs harder to absorb. A sustained contraction would reduce resources available for innovation and market expansion, and could delay the path toward operating breakeven.

Persistent Structural Losses

Ongoing operating and net losses indicate that the current business has not yet converted its product activity into sustainable earnings. Continued losses can erode shareholder value, constrain internal funding capacity, and leave profitability dependent on a material improvement in revenue or expenses.

Weak Cash Generation

Negative operating and free cash flow make the company reliant on existing liquidity or external funding to support its operations and growth. The sharp 2025 deterioration increases financial pressure and reduces flexibility to absorb continued weak revenue or fund commercial investment.

Venus Medtech (Hangzhou), Inc. Class H News

2500 FAQ

What was Venus Medtech (Hangzhou), Inc. Class H’s price range in the past 12 months?
Venus Medtech (Hangzhou), Inc. Class H lowest stock price was HK$0.94 and its highest was HK$3.86 in the past 12 months.
What is Venus Medtech (Hangzhou), Inc. Class H’s market cap?
Venus Medtech (Hangzhou), Inc. Class H’s market cap is HK$434.40M.
When is Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Venus Medtech (Hangzhou), Inc. Class H’s earnings last quarter?
Venus Medtech (Hangzhou), Inc. Class H released its earnings results on Aug 31, 2026. The company reported -HK$0.498 earnings per share for the quarter.
Is Venus Medtech (Hangzhou), Inc. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Venus Medtech (Hangzhou), Inc. Class H pay dividends?
Venus Medtech (Hangzhou), Inc. Class H does not currently pay dividends.
What is Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate?
Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Medtech (Hangzhou), Inc. Class H have?
Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding.
What happened to Venus Medtech (Hangzhou), Inc. Class H’s price movement after its last earnings report?
Venus Medtech (Hangzhou), Inc. Class H reported an EPS of -HK$0.498 in its last earnings report. Following the earnings report the stock price went up 0.5%.
Which hedge fund is a major shareholder of Venus Medtech (Hangzhou), Inc. Class H?
Currently, no hedge funds are holding shares in HK:2500
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology